Bioxyne Limited

Equities

BXN

AU000000BXN6

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:08:23 2024-05-23 pm EDT			5-day change	1st Jan Change
0.006 ^AUD	0.00%		0.00%	-45.45%

May. 14	Bioxyne to Release Shares from Escrow; Shares Up 17%	MT
May. 14	Bioxyne Subsidiary, CY Biopharma Enter Partnership to Advance Novel Psilocybin Therapies in Australia	MT

Bioxyne Limited Reports Earnings Results for the Full Year Ended June 30, 2020

August 30, 2020 at 06:32 pm EDT

Bioxyne Limited announced earnings results for the full year ended June 30, 2020. For the full year, the company announced net loss was AUD 593,095 compared to AUD 1.265 million a year ago. Basic loss per share was AUD 0.0009 compared to AUD 0.002 a year ago.

Latest news about Bioxyne Limited

Bioxyne to Release Shares from Escrow; Shares Up 17%	May. 14	MT
Bioxyne Subsidiary, CY Biopharma Enter Partnership to Advance Novel Psilocybin Therapies in Australia	May. 13	MT
Bioxyne to Raise AU$1.45 Million via Share Issuance	Apr. 17	MT
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Bioxyne Receives License to Manufacture Medical Cannabis, MDMA; Shares Up 50%	Feb. 04	MT
Bioxyne Limited Announces Retirement of N H Chua as Director	Nov. 17	CI
Bioxyne Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Bioxyne Unit Joins Forces to Launch B2B Cannabis Trading Platform in Australia; Shares Slump 11%	23-08-15	MT
Bioxyne Limited Extends Amazon Footprint into US and Japan	23-07-16	CI
Australian Shares Track Gains of Wall Street Peers Ahead of Inflation Data, Policy Meetings	23-06-13	MT
Bioxyne Launches Online Healthcare with Technology Partner InstantScripts; Shares Decline 8%	23-06-12	MT
Bioxyne Limited Appoints Jason Hine as Director	23-05-22	CI
Bioxyne Acquires Breathe Life Sciences	23-05-22	MT
Bioxyne Limited acquired Breathe Life Sciences Pty Ltd.	23-05-18	CI
Bioxyne Proceeds With Breathe Life Sciences Acquisition; Shares Fall 4%	23-03-19	MT
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Bioxyne's Fiscal H1 Revenue Declines	23-01-27	MT
Bioxyne to Acquire Health, Wellness Peer Breathe Life Sciences; Shares Gain 4%	22-12-18	MT
Bioxyne Limited entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million.	22-12-18	CI
Bioxyne Limited Announces Joining of Mr. Sam Watson the Board as Joint Chief Executive Officer	22-12-18	CI
Bioxyne Sells 49% Stake in Direct Selling Business	22-10-24	MT
Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited for $1 million.	22-10-23	CI
Bioxyne Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-29	CI
Bioxyne Limited Announces Board Changes	22-06-07	CI
Bioxyne Posts Higher Sales Revenue in First Nine-Months of FY22	22-04-27	MT

Chart Bioxyne Limited

Duration

Period

More charts

Company Profile

Bioxyne Limited is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries Japan, Australia, the United Kingdom, and Czechia. The Company direct sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOXYNE LIMITED	-45.45%	8.14M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research